This document describes the adversarial validation methodology underpinning the AimwellBio PROCEED / DELAY / KILL verdict system. It covers the four-agent audit architecture, ground truth framework, historical decision corpus, verdict generation thresholds, and alignment with ICH statistical and clinical guidance. This methodology is the operational core of what we call REGTECH — the emerging discipline of applying institutional-grade adversarial validation to AI-generated biopharma science before it enters regulatory, investment, or clinical decisions.
Adversarial validation is not peer review. It is not quality assurance. It is a structured attempt to find the flaw in a piece of AI-generated biopharma science before that flaw is found by the FDA, a trial monitoring committee, or an investment committee during due diligence.
The AimwellBio methodology runs four independent AI agents against every brief submitted for validation. Each agent approaches the brief from the adversarial position of a different institutional challenger — regulatory reviewer, competitive intelligence analyst, capital risk assessor, and clinical trial failure analyst. The four agents do not collaborate during the audit. They produce independent findings, which are then synthesized into a consensus verdict.
The output is a PROCEED, DELAY, or KILL verdict — with a full audit trail showing exactly which agent identified which risk, against which ground truth reference, with what confidence level. The verdict is not a recommendation. It is an institutional accountability document.
Core principle: Every AI-generated biopharma brief contains at least one assumption that has not been validated against historical regulatory outcomes. The methodology exists to find that assumption before it compounds into a decision.
AI-generated biopharma intelligence has proliferated faster than the institutional capacity to verify it. Clinical briefs, competitive landscapes, regulatory filing summaries, and trial design recommendations are now routinely generated by large language models and delivered to decision-makers as if they carried the same epistemic weight as data-grounded analysis.
They do not. Large language models optimize for plausibility, not accuracy. A model trained on regulatory literature will generate statistically plausible regulatory arguments. Those arguments will be internally coherent. They will not be grounded in the specific approval history, complete response letter precedents, or endpoint failure rates that a regulatory expert at FDA would reference.
The consequence is not that AI is wrong. It is that AI is selectively wrong in the direction of the outcome the user was hoping for — because the prompts are written by people who have a position. The adversarial agent is the antidote: it is prompted to disprove, not to confirm.
This is the validation problem that REGTECH is designed to solve. It is not a future problem. It is the reason organizations are receiving Complete Response Letters on submissions that AI-generated analysis declared low-risk.
The validation layer deploys four independent agents in parallel against every brief. Each agent operates from a distinct adversarial position and references a distinct ground truth corpus. The agents are not aware of each other's findings during the audit phase — independence is a design requirement, not a feature.
Simulates the regulatory reviewer's perspective. Cross-references the brief against historical FDA decisions for the relevant therapeutic area, clinical endpoint type, and statistical design. Identifies gaps between the brief's regulatory claims and precedent.
Maps the competitive landscape at the projected approval date, not the brief date. Identifies approved or late-stage competitors the brief does not account for, and quantifies the market access risk of a landscape the sponsor is not licensing against.
Audits the clinical assumptions in the brief against historical trial failure modes in the same indication. Flags enrollment assumptions, endpoint definitions, and inclusion/exclusion criteria that match the failure signatures in the historical corpus.
Constructs the downside scenarios the brief did not model. Quantifies capital exposure under regulatory delay, competitive displacement, and trial failure scenarios. Produces the IC stress package the brief's sponsors had no incentive to include.
After the independent audit phase, a synthesis layer produces the consensus verdict. Where agents disagree, the disagreement is documented — not suppressed. A split verdict (e.g., Regulatory PROCEED, Clinical DELAY) is a DELAY at the consensus level, with the specific risk source identified in the audit trail.
The adversarial agents are only as credible as their reference corpus. The AimwellBio ground truth framework is built from publicly available regulatory and clinical data — not proprietary or confidential sources. This is deliberate: institutional credibility requires verifiability.
Scope boundary: The ground truth corpus does not include proprietary sponsor data, confidential regulatory submissions, or non-public clinical datasets. Validation outputs are based solely on publicly available ground truth. This is a design choice: institutional defensibility requires that the reference corpus be auditable.
The three-verdict framework is designed for institutional decision-making — not analytical nuance. Each verdict has a specific operational meaning that does not require interpretation at the board level.
No material adversarial finding across all four agents. The brief's core claims are consistent with historical regulatory outcomes for analogous assets. Proceed with the decision this brief was prepared to support. Audit trail archived.
At least one agent identified a material discrepancy between the brief's claims and historical ground truth. The decision this brief supports should be delayed pending resolution of the identified risk(s). Specific flags documented in audit trail.
Multiple agents identified material failures, or at least one agent identified a structural flaw that invalidates the brief's core premise. The decision this brief was prepared to support should not proceed in its current form. Full failure analysis in audit trail.
Verdict confidence is expressed as a percentage. A 94% confidence DELAY means that across the historical corpus of analogous audit scenarios, 94 out of 100 reached the same verdict when the same risk pattern was present. Confidence intervals are included in the full audit trail and calibrated quarterly against new regulatory decision data.
The methodology is aligned with — not certified by — the following regulatory guidance frameworks. Alignment means the validation logic and statistical treatment referenced in each guideline are incorporated into the relevant agent's audit criteria. It does not constitute endorsement by the referenced bodies.
| Guideline | Alignment Area |
|---|---|
| ICH E9(R1) · 2020 | Statistical methodology for clinical trials; estimand framework for regulatory claims; sensitivity analysis requirements. Agent 01 (Regulatory) references E9(R1) when auditing endpoint definitions and statistical design claims. |
| ICH E10 | Choice of control group in clinical trials. Agent 03 (Clinical Failure) cross-references control group selection against E10 guidance when auditing trial design assumptions. |
| ICH E6(R3) · GCP | Good clinical practice standards for trial conduct. Agent 03 references E6(R3) compliance indicators when auditing clinical design assumptions against site feasibility and protocol adherence risk. |
| FDA CDER Guidance for Industry | Therapeutic area-specific guidance documents are referenced by Agent 01 for endpoint acceptability, labeling implications, and approval pathway claims. |
| EMA AI/ML Qualification Opinion | AI-specific regulatory considerations are incorporated into the framework's own documentation standards — ensuring the validation outputs themselves meet emerging AI governance expectations. |
The methodology validates the consistency of AI-generated science against publicly available ground truth. It does not validate proprietary data, clinical data not yet in the public record, or decisions that have no historical regulatory analogue. Novel mechanisms, first-in-class assets, and unprecedented regulatory pathways require human expert judgment that the adversarial agent layer is designed to flag — not replace.
The verdict is an institutional accountability tool, not a regulatory determination. A PROCEED verdict does not mean the FDA will approve. A KILL verdict does not mean the asset is unviable. It means the brief, as presented, failed the adversarial test against the historical ground truth corpus available at the time of audit.
Methodology updates are published quarterly as new regulatory decision data is incorporated. Members receive notification when corpus updates materially affect active verdict confidence scores.
Clear cell renal cell carcinoma was added as the seventh vertical via a different ingest pipeline than the original six indications. We disclose the method here so partners know exactly what they are looking at and how it differs from the rest of the corpus.
A regex-based RCC-relevance filter was applied to drop drug-name false positives. Signals were retained only if the title or body contained explicit RCC terminology (clear cell renal cell carcinoma, renal cell carcinoma, kidney cancer, nephrectomy, von Hippel-Lindau, papillary RCC, chromophobe RCC), or named an RCC-approved therapeutic in unambiguous RCC context (belzutifan, Welireg, cabozantinib, Cabometyx, tivozanib, Fotivda, sunitinib, axitinib, pazopanib). SEC filings from the 20 RCC-focused pharma tickers were retained as the regulatory paper trail of those companies.
[ccrcc, renal, oncology] so it surfaces from any of the three chip filters on /signals and /atlas.Why this matters: Methodology variance between verticals matters. The other six verticals use a wider net — top-12 keywords against general PubMed and ClinicalTrials.gov queries, with no post-process filter. ccRCC uses a narrower, RCC-specific net with a quality-gate filter. The other six verticals report 95%+ retention; ccRCC reports 40.8%. Disclosing this prevents the appearance that all verticals follow identical pipelines.
The full ingest manifest is at tools/scout-ingest/sources/ccrcc.yml in the project repo. The keymap that drives secondary tagging is at tools/scout-ingest/normalizer.py. The post-process filter logic is in the run log at tools/scout-ingest/runs/.
Signals tagged in multiple verticals (e.g., a SEC filing classified as both oncology and renal) appear in both indication feeds with the same canonical signal ID. The chip filter on /signals deduplicates these at render time so users see each unique signal once, but raw per-feed counts will sum to more than the deduplicated unique total.
As of 2026-05-08, the live deduplicated corpus is:
Partners modeling allocations should use the deduplicated unique total (8,004) for capacity claims; the per-feed raw totals (e.g., 1,706 in renal, 1,761 in oncology) are valid for indication-specific scoping.
REGTECH — regulatory technology applied to the validation of AI-generated biopharma intelligence — is not an emerging category. It is a present requirement that most organizations are ignoring. The FDA is already developing internal capabilities to detect AI-generated regulatory submissions. The question is whether your submissions will survive that scrutiny.
Every organization in this industry is now making regulatory, investment, and clinical decisions informed by AI-generated science. The organizations building adversarial validation into that pipeline now are creating an institutional capability that compounds. The organizations that are not are accumulating unverified assumptions at the same rate — but with no visibility into where the exposure sits.
The AimwellBio methodology is the first published adversarial validation framework built specifically for AI-generated biopharma science. Members have access to the full methodology, the verdict corpus, and the capability to run their own audits. Non-members are making decisions against a brief that no one has challenged.
The methodology is publicly available. The validation layer — the capability to run your own PROCEED / DELAY / KILL audits against this framework — is members-only. Here is what is already running inside member organizations right now.
Submit any AI-generated brief for a real-time four-agent adversarial audit. PROCEED / DELAY / KILL verdict with full audit trail delivered within 3 minutes.
Every verdict archived with full agent-level finding detail. Present to your investment committee or regulatory team as a documented due diligence artifact.
Continuous monitoring of FDA decisions, CRL patterns, and approval precedents in your therapeutic area. Verdict confidence scores updated quarterly with new ground truth data.
Pre-formatted audit output structured for investment committee or board presentation. Verdict-first, no interpretation required, full agent source documentation included.
Full access to the ground truth corpus: 40,000+ historical FDA decisions, CRL patterns, and trial failure data that power the adversarial agents. Query the corpus directly.
Multi-seat workspace for regulatory, BD, and clinical teams. Share audit findings across functions. One validation layer, visible to every stakeholder who needs it.
THE ORGANIZATIONS ALREADY USING THIS ARE BUILDING A VALIDATION ADVANTAGE THAT COMPOUNDS.
Every audit run trains your institutional memory for what AI-generated biopharma science gets wrong. The longer you wait, the larger the gap between what they know and what you are guessing at.
Request Access to the Validation Layer →Submit your first AI-generated brief for adversarial validation. PROCEED / DELAY / KILL verdict in under 3 minutes. Full audit trail included.
For institutional & sovereign mandates: view sovereign deployment options